Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has issued an announcement.
Racura Oncology Ltd, an ASX-listed oncology-focused biotech, develops cancer therapies aimed at addressing unmet medical needs in oncology markets. The company’s activities center on advancing innovative treatments that can strengthen its clinical portfolio and market positioning.
The company has applied for quotation of 481,027 new fully paid ordinary shares on the ASX, following the exercise or conversion of existing options or other convertible securities. The additional quoted shares modestly expand Racura’s share capital base, potentially improving liquidity in its stock and reflecting some ongoing support from holders of its convertible instruments.
More about Race Oncology Ltd.
Racura Oncology Ltd, listed on the ASX under the code RAC, operates in the biotechnology and pharmaceutical sector with a focus on oncology. The company is engaged in developing cancer-related therapies and treatments for patients, targeting opportunities in the clinical and commercial oncology markets.
Average Trading Volume: 199,628
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$499.9M
For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.